http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6241136-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c19aaa6b5ffdbeb95eaafc820ff0cb86 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-06 |
| filingDate | 2009-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f94d606d13750eb6c9f443a806e4bc34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_462b8d4747a91372d8311002195db58c |
| publicationDate | 2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6241136-A2 |
| titleOfInvention | ORAL FORMULATIONS OF CONTROLLED RELEASE OF IONIC CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR THE PREVENTION OF ARRITHMIAS |
| abstract | 1. A method for preventing arrhythmia in a mammal, comprising: (a) determining whether the mammal is a weak metabolizer (DM) of cytochrome P450 (CYP) 2D6 or a broad metabolizer of cytochrome P450 (CYP) 2D6; and (b) administering to the mammal a therapeutically effective amount of a composition comprising an ionic channel modulating compound having the structure: including enantiomeric, diastereomeric and geometric isomers isolated therefrom and mixtures thereof or a pharmaceutically acceptable solvate or salt. Of the same; where R4 and R5 are independently selected from hydroxy and C1-C6alkoxy. 2. The method of claim 1 wherein the composition comprises a monohydrochloride salt of the formula: 3. A method for the prevention of arrhythmia in a mammal, comprising: (a) determining if the mammal is a weak metabolizer (DM ) of cytochrome P450 (CYP) 2D6 or a broad metabolizer of cytochrome P450 (CYP) 2D6; and (b) administer to the mammal a sufficient amount of an ion channel modulator compound to achieve a blood plasma concentration (Cmax) of between about 0.1 µg / ml and about 10 µg / ml for at least a time, where said Ionic channel modulator compound comprises an ion channel modulator compound of the formula: including enantiomeric, diastereomeric and geometric isomers isolated therefrom and mixtures thereof, or a pharmaceutically acceptable solvate or salt thereof: where R4 and R5 are selected independently of hydroxy and C1-C6alkoxy. |
| priorityDate | 2007-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048 |
Total number of triples: 31.